Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.

IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.

Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted 4-year RP data in an AAO-driven October.

October spotlights eye-care breakthroughs: phase 3 gene therapies, sustained delivery, and AAO trial data, plus 3 FDA clearances shaping retina, cataract, and TED care.

The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.

Andrew G. Lee, MD, and Drew Carey, MD, break down the visual safety of flow-diverting stents for carotid-ophthalmic aneurysms.

Christopher J. Rapuano, MD, discusses emergency eye care access, retina advances and responsible AI use in ophthalmology.

Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.